10-Q: RetinalGenix Technologies Reports First Quarter 2024 Results, Cites Going Concern Uncertainty

RetinalGenix Technologies reported a net loss of $2.146 million for the first quarter of 2024 and highlighted substantial doubt about its ability to continue as a going concern.

Summary

• RetinalGenix Technologies, an ophthalmic research and development company, reported its financial results for the quarter ended March 31, 2024.
• The company incurred a net loss of $2,145,876, or $0.12 per share, compared to a net loss of $510,643, or $0.03 per share, for the same period in 2023.
• Operating expenses totaled $2,144,916, which included $1,732,834 in stock-based compensation.
• The company's cash balance was $50,386 as of March 31, 2024.
• RetinalGenix has an accumulated deficit of approximately $13,255,000 and liabilities of approximately $1,569,000.
• The company is dependent on affiliates, including Sanovas, for much of its financing.
• The company anticipates needing an additional $12,200,000 to complete product development and build infrastructure.
• There is substantial doubt about the company's ability to continue as a going concern without additional funding.
• The company is in discussions with investment bankers and individual investors regarding raising additional capital and potentially up-listing to the NASDAQ exchange.
• The company has not generated any revenue since its inception.

Sentiment

Score: 2

Explanation: The document paints a very negative picture due to the significant losses, minimal cash, going concern warning, and ineffective internal controls. The company's reliance on related-party funding and lack of revenue generation further contribute to the low sentiment.

Positives

• The company is making progress in its planning for pharmaceutical clinical studies for RTG-2023 and RTG-2024.
• The company is engaged with Pearl IRB for a study on wet macular degeneration, with potential revenue generation in Q1 2025.
• The company is actively pursuing its mission to prevent vision loss and blindness due to ocular and systemic diseases.
• The company has developed two devices: RetinalCamTM and a portable retinal imaging system.

Negatives

• The company has incurred significant net losses since inception and has an accumulated deficit of approximately $13,255,000.
• The company has minimal cash and is heavily reliant on related parties for financing.
• There is substantial doubt about the company's ability to continue as a going concern.
• The company has not generated any revenue since its inception.
• The company's internal controls over financial reporting are ineffective due to a material weakness related to a lack of segregation of duties.
• Research and development expenses decreased by 64% due to lack of available funds.

Risks

• The company's ability to continue as a going concern is uncertain due to its financial condition and dependence on external funding.
• The company may not be able to raise the necessary additional capital to complete product development and commercialization.
• The company's internal controls over financial reporting are ineffective, which could lead to inaccurate financial statements.
• The company has not generated any revenue and may not achieve profitability.
• The company is subject to risks inherent in the establishment of a new business enterprise.
• The company's product development and clinical trials may be delayed or unsuccessful.
• The company may be subject to litigation and claims in the ordinary course of business.

Future Outlook

The company expects to incur operating losses and negative cash flows for at least the next several years and will need to raise additional funds to achieve its strategic goals. The company anticipates needing an additional $12,200,000 to complete product development and build infrastructure. The company is in discussions with investment bankers and individual investors regarding raising additional capital and potentially up-listing to the NASDAQ exchange.

Management Comments

• The company is actively pursuing its mission to prevent vision loss and blindness due to ocular and systemic diseases.
• The company is working to complete product design and testing for RetinalGenixTM and RetinalCamTM.
• The company is focused on developing software tools around the recently acquired DNA/GPS genetic mapping technology.
• The company is building the infrastructure for its sustained growth.

Industry Context

The company operates in the ophthalmic research and development sector, focusing on solutions for screening, monitoring, diagnosing, and treating eye disorders. The company's focus on early detection and treatment of systemic diseases through retinal imaging aligns with the growing trend of using advanced technologies for preventative healthcare. The company's development of in-home monitoring devices also reflects the increasing demand for remote patient care solutions.

Comparison to Industry Standards

• RetinalGenix's financial performance is significantly weaker than established companies in the medical device and pharmaceutical industries, which typically have revenue streams and positive cash flows.
• Companies like Alcon (ALC) and Bausch Health (BHC) in the ophthalmic space have established product portfolios and generate substantial revenue, unlike RetinalGenix which is still in the development phase.
• In the biotech sector, companies like Regeneron (REGN) and Vertex Pharmaceuticals (VRTX) have successfully commercialized products and have strong financial positions, contrasting with RetinalGenix's current financial struggles.
• The level of stock-based compensation expense as a percentage of total expenses is very high compared to industry standards, indicating a heavy reliance on equity-based incentives.
• The company's reliance on related-party funding is not typical for publicly traded companies and raises concerns about financial independence and governance.

Corporate Governance

Related Party Transactions

• The company is related to Sanovas through common ownership and management.
• Sanovas has paid a significant portion of the company's operating expenses.
• The company owes Sanovas approximately $193,000 as of March 31, 2024.
• The company has received advances from related parties totaling $500,789 as of March 31, 2024.
• The company has a sublicense agreement with Sanovas Ophthalmology.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees may be impacted by potential cost-cutting measures or layoffs if the company's financial situation does not improve.
• Customers may be affected by delays in product development and commercialization.
• Suppliers and creditors face the risk of non-payment due to the company's financial difficulties.

Next Steps

• The company plans to complete product design and testing for RetinalGenixTM and RetinalCamTM.
• The company intends to submit RetinalGenixTM for FDA clearance.
• The company will continue the development and expansion of the software tools around the DNA/GPS genetic mapping technology.
• The company will build the infrastructure for its sustained growth.
• The company will conduct pharmaceutical clinical studies for RTG-2023 and RTG-2024.
• The company will continue the Pearl IRB study on wet macular degeneration.
• The company will seek additional funding through equity, debt, or strategic partnerships.

Key Dates

Keywords

RetinalGenix, Ophthalmic, Retinal Imaging, Medical Devices, Pharmaceuticals, Going Concern, Financial Results, Stock-based Compensation, Clinical Trials, Macular Degeneration, Alzheimer's, Capital Raise